HSF1 and urinary bladder cancer: Collectively, our results support the further evaluation of combination therapy with bortezomib plus Hsp72 and/or HSF1 inhibitors in xenograft models of bladder cancer to determine toxicity and therapeutic efficacy and encourage the continued development of more potent heat shock response inhibitors.